Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung …
C Bergonzini, A Leonetti, M Tiseo… - Expert opinion on …, 2020 - Taylor & Francis
Introduction Non-small cell lung cancer (NSCLC) is a highly lethal disease. During the past
20 years, the epidermal growth factor receptor (EGFR) has been a relevant target for …
20 years, the epidermal growth factor receptor (EGFR) has been a relevant target for …
Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? A narrative review
JY Shih, A Inoue, R Cheng, R Varea, SW Kim - Cancers, 2020 - mdpi.com
Simple Summary The chemotherapy agent pemetrexed is currently considered in
combination with other therapies for the treatment of advanced nonsquamous non-small-cell …
combination with other therapies for the treatment of advanced nonsquamous non-small-cell …
[PDF][PDF] 肺癌化疗患者癌因性疲乏影响因素及与生存质量, 睡眠质量的关系研究
汤雅洁， 岳朝丽， 许丽芬， 徐齐宏… - 现代生物医学 …, 2020 - biomed.cnjournals.com
摘要目的: 调查肺癌化疗患者癌因性疲乏情况, 并分析癌因性疲乏与生存质量, 睡眠质量的关系.
方法: 选取2017 年3 月至2019 年11 月期间我院收治的189 例肺癌化疗患者. 分别采用Piper …
方法: 选取2017 年3 月至2019 年11 月期间我院收治的189 例肺癌化疗患者. 分别采用Piper …
Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study
The journey of a thousand miles in lung cancer therapy began with the discovery of
actionable genomic alterations. The two most well described molecular alterations are the …
actionable genomic alterations. The two most well described molecular alterations are the …
Fucoidan with three functions extracted from Sargassum aquifolium integrated rice-husk synthesis dual-imaging mesoporous silica nanoparticle
ZH Lee, MF Lee, JH Chen, MH Tsou, ZY Wu… - Journal of …, 2022 - Springer
In this study, we used the nanoparticle delivery system to reduce the side effect of
conventional cancer treatment-radiation therapy and chemotherapy. We used rice husk …
conventional cancer treatment-radiation therapy and chemotherapy. We used rice husk …
Efficacy of EGFR-TKI plus chemotherapy or monotherapy as first-line treatment for advanced EGFR-mutant lung adenocarcinoma patients with co-mutations
Z Yang, Y Chen, Y Wang, S Wang, M Hu… - Frontiers in …, 2021 - frontiersin.org
Background Co-mutations was associated with poor response to EGFR-TKIs. First-
generation EGFR-TKIs combined with chemotherapy was reported to be more effective than …
generation EGFR-TKIs combined with chemotherapy was reported to be more effective than …
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients with EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Receiving Tyrosine …
MG Ferrara, M Martini, E D'Argento, C Forcella, E Vita… - Clinical lung cancer, 2021 - Elsevier
Background Rapid disease progression of patients with advanced epidermal growth factor
receptor (EGFR)-mutant non–small-cell lung cancer (NSCLC) has been recently associated …
receptor (EGFR)-mutant non–small-cell lung cancer (NSCLC) has been recently associated …
Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a …
Q Wang, W Gao, F Gao, S Jin, T Qu, F Lin, C Zhang… - BMC cancer, 2021 - Springer
Background To compare the benefits and explore the cause of acquired resistance of
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination …
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination …
Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma
R Li, X Zhou, H Yao, L Li - Journal of Drug Targeting, 2020 - Taylor & Francis
Non-small cell lung carcinoma (NSCLC) is a malignant tumour with poor prognosis and high
mortality. Platinum-based dual-agent chemotherapy is the main therapeutic regimen for this …
mortality. Platinum-based dual-agent chemotherapy is the main therapeutic regimen for this …
Identification of a rare EGFR exon 18 mutation in lung adenocarcinoma using targeted next-generation sequencing as a tool for precision medicine
P Jha, V Trivedi, R Biswal, P Chandrani… - Cancer Research …, 2023 - journals.lww.com
DISCUSSION Introduction to EGFR EGFR belongs to the erythroblastic leukemia viral
oncogene homolog (ERBB) family of receptor tyrosine kinases and is alternatively known as …
oncogene homolog (ERBB) family of receptor tyrosine kinases and is alternatively known as …